Recently, researchers in Australia tested baricitinib, a drug used for rheumatoid arthritis, in people newly diagnosed with Type‑1 diabetes, showing promising results for early intervention.

With the prevalence of diabetes quadrupling in recent decades and currently impacting more than 500 million people in the world, it is no surprise that the technology for insulin delivery has also ...